Jason R. Dobson - Concepedia

Author

Jason R. Dobson

University of Massachusetts Chan Medical School ORCID

Also Known As

Dobson, Jason R., J Dobson, J.R.E. Dobson, Jason Dobson, Jason R Dobson, Jason R. Dobson, Zhang, Hailei

Publications

3.9K

Citations

H-Index

Concepts

All Affiliations

University of Massachusetts Chan Medical School University of Vermont Dana-Farber Cancer Institute Novartis (Switzerland)Brown University

About

Jason R. Dobson is an author at University of Massachusetts Chan Medical School specializing in medicine, cell biology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	12	1.6K
2	Cell Biology	9	9	1.4K
3	Natural Sciences	5	5	224
4	Engineering	1	1	45
5	Biology	1	1	61

Jason R. Dobson

Publications

3.6K

Citations

H-Index

Page 1

	Year	Citations
Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes Mark D.M. Leiserson, Fabio Vandin, Hsin-Ta Wu, Nature Genetics	2014	969
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases Ying-Nan P. Chen, Matthew J. LaMarche, Ho Man Chan, Nature Cancer ResearchAllosteric InhibitionSignal TransductionSignaling PathwayMedicine	2016	893
A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas Jeffrey R. Infante, Philippe A. Cassier, John F. Gerecitano, Clinical Cancer Research	2016	315
Genomic Analysis of Nasopharyngeal Carcinoma Reveals TME-Based Subtypes Li Zhang, Kenzie D. MacIsaac, Ting Zhou, Molecular Cancer Research	2017	212
Runx2 Transcriptional Activation of Indian Hedgehog and a Downstream Bone Metastatic Pathway in Breast Cancer Cells Jitesh Pratap, John J. Wixted, Tripti Gaur, Cancer Research SclerostinDevelopmental BiologySignaling PathwayBone Morphogenic ProteinMedicine	2008	185
A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors Birgit Geoerger, Franck Bourdeaut, Steven G. DuBois, Clinical Cancer Research	2017	182
Genomic occupancy of Runx2 with global expression profiling identifies a novel dimension to control of osteoblastogenesis Hai Wu, Troy W. Whitfield, Jonathan A. R. Gordon, Genome biology	2014	145
Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours Jordi Rodón, Guillem Argilés, Roisín M. Connolly, British Journal of Cancer Tumor BiologySingle-agent Wnt974OncologyMedicinePathology	2021	144
The BRG1 chromatin remodeling enzyme links cancer cell metabolism and proliferation Qiong Wu, Pasil Madany, Jason R. Dobson, Oncotarget Metabolic RemodelingCancer BiologyEpigeneticsTumor BiologyCancer Cell Biology	2016	70
Runx1 stabilizes the mammary epithelial cell phenotype and prevents epithelial to mesenchymal transition Deli Hong, Terri Messier, Coralee E. Tye, Oncotarget	2017	69

Page 1